WEKO3
アイテム
Long-Term Clinical Outcomes of the Patients with Chronic Myeloid Leukemia Treated with Nilotinib as the 1st-Line Tyrosine Kinases Inhibitor at the Kindai university hospital
https://doi.org/10.15100/0002001137
https://doi.org/10.15100/00020011371176faef-0d66-4208-803d-ab1f5bce0d09
| 名前 / ファイル | ライセンス | アクション |
|---|---|---|
AA0050842X-20240600-0015.pdf
|
|
| Item type | 紀要論文 / departmental bulletin paper(1) | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 公開日 | 2024-06-20 | |||||||||||||||||||
| タイトル | ||||||||||||||||||||
| タイトル | Long-Term Clinical Outcomes of the Patients with Chronic Myeloid Leukemia Treated with Nilotinib as the 1st-Line Tyrosine Kinases Inhibitor at the Kindai university hospital | |||||||||||||||||||
| 言語 | en | |||||||||||||||||||
| 作成者 |
Hirase, Chikara
× Hirase, Chikara
× Matsumura, Itaru
× Kumode, Takahiro
× Serizawa, Kentaro
× Morita, Yasuyoshi
× Tanaka, Hirokazu
× Fukuoka, Kazuya
|
|||||||||||||||||||
| 言語 | ||||||||||||||||||||
| 言語 | eng | |||||||||||||||||||
| キーワード | ||||||||||||||||||||
| 主題 | chronic myeloid leukemia, molecular targeted therapies, nilotinib, outcome assessment | |||||||||||||||||||
| 内容記述 | ||||||||||||||||||||
| 内容記述タイプ | Abstract | |||||||||||||||||||
| 内容記述 | Background: Nilotinib has been shown to be a more potent tyrosine kinase inhibitor of BCR::ABL1 than imatinib. We evaluated long-term efficacy and safety based on the 7-year follow-up data in patients with newly diagnosed chronic myeloid leukemia (CML) who were treated with nilotinib as the 1st-line therapy (1L-NIL) at the Kindai university hospital. Methods: In this single-center, observational study, we enrolled patients with newly diagnosed CML in chronic phase (CML-CP) who received 1L-NIL since December 2010, when nilotinib received regulatory approval for CML-CP in Japan. The primary endpoint was overall survival (OS) of the 1L-NIL patients. In addition, we analyzed molecular responses and safety profiles as the key secondary endpoints. Results: The median observation period was 6.8 (range: 1.2-12.3) years. The estimated OS and progression-free survival rates of the 1L-NIL patients (n=25) were both 95.5%. By 18 months, the cumulative achievement rates of major molecular response (MMR) and MR4.5 were 81.3% and 25.0%, respectively. Adverse events (AEs) occurred in 21 of 23 patients (91.3%) with Grade ≥3 in 8 of 23 patients (34.8%). We observed no unexpected serious AEs in this research. Conclusions: Our data showed that the efficacy of nilotinib persisted over the 7-year follow-up and long-term administration of nilotinib was not associated with unacceptable late toxic effects at the Kindai university hospital. |
|||||||||||||||||||
| 言語 | en | |||||||||||||||||||
| 出版者 | ||||||||||||||||||||
| 出版者 | The Kindai University Medical Association | |||||||||||||||||||
| 言語 | en | |||||||||||||||||||
| 資源タイプ | ||||||||||||||||||||
| 資源タイプ識別子 | http://purl.org/coar/resource_type/c_6501 | |||||||||||||||||||
| 資源タイプ | departmental bulletin paper | |||||||||||||||||||
| 出版タイプ | ||||||||||||||||||||
| 出版タイプ | AM | |||||||||||||||||||
| 出版タイプResource | http://purl.org/coar/version/c_ab4af688f83e57aa | |||||||||||||||||||
| ID登録 | ||||||||||||||||||||
| ID登録 | 10.15100/0002001137 | |||||||||||||||||||
| ID登録タイプ | JaLC | |||||||||||||||||||
| 収録物識別子 | ||||||||||||||||||||
| 収録物識別子タイプ | PISSN | |||||||||||||||||||
| 収録物識別子 | 03866092 | |||||||||||||||||||
| 収録物識別子 | ||||||||||||||||||||
| 収録物識別子タイプ | EISSN | |||||||||||||||||||
| 収録物識別子 | 24327166 | |||||||||||||||||||
| 書誌情報 |
en : ACTA MEDICA KINDAI UNIVERSITY 巻 49, 号 1, p. 15-25, 発行日 2024-06 |
|||||||||||||||||||
